The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2024, more than 1,500, including a record-breaking number of clinical based Late-breaking Abstracts. SITC is proud to announce the titles and authors for the clinical Late-breaking Abstracts (LBA). The abstracts will be presented at SITC's upcoming 39th Annual Meeting & Pre-Conference Programs taking place Nov. 6–10, 2024, in Houston, TX and virtually.
MILWAUKEE, Oct. 30, 2024 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) received an incredible number of abstract submissions in 2024, more than 1,500, including a record-breaking number of clinical based Late-breaking Abstracts. SITC is proud to announce the titles and authors for the clinical Late-breaking Abstracts (LBA). The abstracts will be presented at SITC's upcoming 39th Annual Meeting & Pre-Conference Programs taking place Nov. 6–10, 2024, in Houston, TX and virtually.
"We are excited to incorporate these clinical abstracts into an already impressive lineup of abstracts that will be presented at SITC. The Late-breaking Abstracts this year will only focus on late-breaking data from interventional clinical trials in humans and will enhance the incredible science offered at the 39th Annual Meeting," said SITC President Leisha A. Emens, MD, PhD. "SITC is committed to accelerating the approval of 100 novel agents by 2034, and providing a platform to showcase the latest clinical advancements at our Annual Meeting is an important component of this goal."
The Late-breaking Abstracts with oral presentations at the 39th Annual Meeting are:
- (1463) Coformulated vibostolimab/pembrolizumab plus chemotherapy as first-line therapy vs atezolizumab plus chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): Randomized, phase 3 KEYVIBE-008
Jacob Sands, MD – Dana-Farber Cancer Institute
Session 104: Clinical Late-Breaking Abstract Session – Friday, Nov. 8, 2024 - 11:45 a.m. CST
- (1492) Telomere-Targeting agent THIO in sequence with cemiplimab demonstrates long-term therapeutic benefits beyond treatment cessation - a phase 2 THIO-101 trial in advanced ICI resistant NSCLC patients
Victor Zaporojan, MD - Maia Biotechnology Inc.
Session 104: Clinical Late-Breaking Abstract Session – Friday, Nov. 8, 2024 - 11:45 a.m. CST
- (1472) A phase 1/2 study evaluating the safety and efficacy of autologous TAC T cells in subjects with claudin 18.2+ advanced solid tumors
Ecaterina E. Dumbrava, MD – The University of Texas MD Anderson Cancer Center
Session 106d: Biotech Breakthroughs - Solid Tumor IO at the Tipping Point – Friday, Nov. 8, 2024 – 1:45 p.m. CST
- (1504) Primary analysis of the registration-intended cohort of patients with anti–PD-1–failed melanoma from the IGNYTE trial of RP1 plus nivolumab, including clinical subgroup and initial biomarker data
Michael Wong, MD, PhD, FRCPC – The University of Texas MD Anderson Cancer Center
Session 204: Clinical Late-Breaking Abstract Session – Saturday, Nov. 9, 2024 - 11:45 a.m. CST
- (1470) START001: A Phase 1/2 study of Invikafusp alfa (STAR0602), a first-in-class TCR β chain-targeted bispecific antibody, as monotherapy in patients with antigen-rich solid tumors resistant to anti-PD(L)1
James L. Gulley, MD, PhD – National Cancer Institute
Session 204: Clinical Late-Breaking Abstract Session – Saturday, Nov. 9, 2024 - 11:45 a.m. CST
The full abstracts will be available on Nov. 5 at 9 a.m. EST as a supplement published in the Journal for ImmunoTherapy of Cancer (JITC).
Clinical Late-Breaking Abstract Sessions with oral abstract presentations will take place on Friday, Nov. 8 from 11:45 a.m.–12:15 p.m. CT and Saturday, Nov. 9 from 11:45 a.m.–12:15 p.m. CT in Hall A3 at the George R. Brown Convention Center. In addition, Late-breaking Abstract posters will be presented in the Exhibit and Poster Hall in Houston, TX and the virtual ePoster Hall beginning Friday, Nov. 8 at 9 a.m. CT.
To learn more about the Late-breaking Abstracts, visit the 39th Annual Meeting & Pre-Conference Programs website.
About SITC
The Society for Immunotherapy of Cancer (SITC) is the world's leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Established in 1984, SITC, a 501(c)(3) not-for-profit organization, serves scientists, clinicians, academicians, patients, patient advocates, government representatives and industry leaders from around the world. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere. To learn more, visit http://www.sitcancer.org and follow us on X, LinkedIn, and YouTube.
Media Contact
Thomas Martin, Societry for Immunotherapy of Cancer, 414-271-2456, [email protected], www.sitcancer.org
SOURCE Societry for Immunotherapy of Cancer
Share this article